MERTK and acute myeloid leukemia: Similarly, a number of selective Mertk inhibitors are also under preclinical development including UNC569 (acute lymphoblastic leukemia (ALL)) [66], UNC1062 (metastatic melanoma) [33], UNC1666 (AML) [67] and UNC2025 (ALL and AML) [68].